P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study

Kwan, 2000, Early identification of refractory epilepsy, N Engl J Med, 342, 314, 10.1056/NEJM200002033420503 Kwan, 2010, Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies, Epilepsia, 51, 1069, 10.1111/j.1528-1167.2009.02397.x Tishler, 1995, MDR1 gene expression in brain of patients with medically intractable epilepsy, Epilepsia, 36, 1, 10.1111/j.1528-1157.1995.tb01657.x Volk, 2005, Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures, Brain, 128, 1358, 10.1093/brain/awh437 van Vliet, 2007, Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats, J Pharmacol Exp Ther, 322, 141, 10.1124/jpet.107.121178 Bankstahl, 2008, Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus, Epilepsy Res, 82, 70, 10.1016/j.eplepsyres.2008.07.007 Brandt, 2006, The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy, Neurobiol Dis, 24, 202, 10.1016/j.nbd.2006.06.014 Aronica, 2004, Expression and cellular distribution of high- and low-affinity neurotrophin receptors in malformations of cortical development, Acta Neuropathol, 108, 422, 10.1007/s00401-004-0906-3 Sisodiya, 2002, Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy, Brain, 125, 22, 10.1093/brain/awf002 Liu, 2012, Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy, Brain, 135, 3115, 10.1093/brain/aws147 Lubberink, 2007, J Cereb Blood Flow Metab, 27, 424, 10.1038/sj.jcbfm.9600349 Giacomini, 2010, Membrane transporters in drug development, Rev Drug Discov, 9, 215, 10.1038/nrd3028 Wagner, 2009, A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)[11C]verapamil and PET, J Nucl Med, 50, 1954, 10.2967/jnumed.109.063289 Kuntner, 2010, Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET, Eur J Nucl Med Mol Imaging, 37, 942, 10.1007/s00259-009-1332-5 Bankstahl, 2011, A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier, J Neurosci, 31, 8803, 10.1523/JNEUROSCI.6616-10.2011 Anton-Rodriguez, 2010, 2935 Feng, 1993, A study on statistically reliable and computationally efficient algorithms for generating local cerebral blood flow parametric images with positron emission tomography, IEEE Trans Med Imaging, 2, 182, 10.1109/42.232247 Abrahim, 2008, Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients, Eur J Nucl Med Mol Imaging, 35, 116, 10.1007/s00259-007-0556-5 Muzi, 2009, Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using 11C-Verapamil in the Brain: Studies of Healthy Humans, J Nucl Med, 50, 1267, 10.2967/jnumed.108.059162 Friston, 1997, Testing for anatomically specified regional effects, Hum Brain Mapp, 5, 133, 10.1002/(SICI)1097-0193(1997)5:2<133::AID-HBM7>3.0.CO;2-4 Langer, 2007, Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil, Epilepsia, 48, 1774, 10.1111/j.1528-1167.2007.01116.x Bonnett, 2012, Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial, Lancet Neurol, 11, 331, 10.1016/S1474-4422(12)70018-2 Zhang, 2011, In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein, Epilepsia, 52, 1894, 10.1111/j.1528-1167.2011.03140.x Baltes, 2007, Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays, J Pharmacol Exp Thers, 320, 331, 10.1124/jpet.106.102491 Lombardo, 2008, Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs, Curr Neurovasc Res, 5, 82, 10.2174/156720208784310196 Kimchi-Sarfaty, 2007, A “silent” polymorphism in the MDR1 gene changes substrate specificity, Science, 315, 525, 10.1126/science.1135308 Westover, 2012, Revising the “Rule of Three” for inferring seizure freedom, Epilepsia, 53, 368, 10.1111/j.1528-1167.2011.03355.x Bauer, 2012, Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data, Clin Pharmacol Ther, 91, 227, 10.1038/clpt.2011.217 Baron, 1983, Brain regional pharmacokinetics of 11C-labeled diphenylhydantoin: positron emission tomography in humans, Neurology, 33, 580, 10.1212/WNL.33.5.580 Potschka, 2010, Modulating P-glcoprotein regulation: future perspectives for pharmacoresistant epilepsies?, Epilepsia, 51, 1333, 10.1111/j.1528-1167.2010.02585.x